Sequential transdermal estrogen-progestin therapy induced a significant reduction in fasting serum homocysteine levels in postmenopausal women. The addition of folic acid supplementation for 6 months did not further lower the homocysteine concentrations
International audienceMild hyperhomocysteinemia is a risk factor for both ischaemic heart disease an...
Background. Many postmenopausal women currently receive hormone replacement therapy. The use of low-...
Since the identification of homocysteine (Hcy) as a risk factor for cardiovascular disease, it has b...
Sequential transdermal estrogen-progestin therapy induced a significant reduction in fasting serum h...
Plasma homocysteine, which is increased after menopause, can be a risk factor for cardiovascular dis...
OBJECTIVE: The aim of our randomized, controlled trial was to verify the effect of folic acid supple...
Homocysteine, a sulfur-containing amino acid is formed during the metabolism (remethylation or trans...
Objective: To assess the impacts of HRT (Hormone Replacement Therapy) and supplementation of folic a...
Serum homocysteine levels may be lowered by hormone replacement therapy, but randomized controlled t...
Serum homocysteine levels may be lowered by hormone replacement therapy, but randomized controlled t...
Objective: To compare the long-term effects of oral and transdermal hormone replacement therapy (HRT...
Objective To evaluate the effect of two different hormone therapy (HT) doses on fasting and post-met...
Background. Many postmenopausal women currently receive hormone replacement therapy. The use of low-...
International audienceMild hyperhomocysteinemia is a risk factor for both ischaemic heart disease an...
Background. Many postmenopausal women currently receive hormone replacement therapy. The use of low-...
Since the identification of homocysteine (Hcy) as a risk factor for cardiovascular disease, it has b...
Sequential transdermal estrogen-progestin therapy induced a significant reduction in fasting serum h...
Plasma homocysteine, which is increased after menopause, can be a risk factor for cardiovascular dis...
OBJECTIVE: The aim of our randomized, controlled trial was to verify the effect of folic acid supple...
Homocysteine, a sulfur-containing amino acid is formed during the metabolism (remethylation or trans...
Objective: To assess the impacts of HRT (Hormone Replacement Therapy) and supplementation of folic a...
Serum homocysteine levels may be lowered by hormone replacement therapy, but randomized controlled t...
Serum homocysteine levels may be lowered by hormone replacement therapy, but randomized controlled t...
Objective: To compare the long-term effects of oral and transdermal hormone replacement therapy (HRT...
Objective To evaluate the effect of two different hormone therapy (HT) doses on fasting and post-met...
Background. Many postmenopausal women currently receive hormone replacement therapy. The use of low-...
International audienceMild hyperhomocysteinemia is a risk factor for both ischaemic heart disease an...
Background. Many postmenopausal women currently receive hormone replacement therapy. The use of low-...
Since the identification of homocysteine (Hcy) as a risk factor for cardiovascular disease, it has b...